The Peptide Split: How GLP-1s, Lutathera, Vosoritide, and Peptide Cancer Vaccines Are Quietly Rewriting Medicine While BPC-157, TB-500, MOTS-c, and the Wellness Grift Borrow Their Halo
Quick Links: Knowledge Base, Podcast, and Social
Knowledge Base — search and filter every article and podcast episode by topic, section, and keyword: kb.onhealthcare.tech
Listen to the Podcast — every article is also available as an audio episode. Free subscribers get the public episodes; paid subscribers get the full archive including subscriber-only episodes. Listen on Apple Podcasts, Spotify, or browse all episodes on the Substack Podcast page.
For paid subscribers — your subscription unlocks the entire research archive (538+ deep-dives), every paid podcast episode, and full search inside the Knowledge Base. To listen to paid episodes in Apple or Spotify, link your Substack subscription via the show settings on those platforms (instructions inside the Substack app under Subscriptions → Podcast).
For free subscribers — free posts and free podcast episodes are always public on Apple/Spotify and Substack. Upgrade any time at onhealthcare.tech/subscribe to access the paid archive and paid episodes.
Follow on Social — X · YouTube · TikTok · Instagram
Video Preview
🎧 Podcast
Table of Contents
Video Preview
Podcast
Abstract
Section one: peptides are not supplements, they are programmable physiology
Paywall
Section two: GLP-1s proved peptide drugs can change hard outcomes, not just biomarkers
Section three: metabolic peptides are collapsing disease categories
Section four: peptides as oncology delivery systems
Section five: rare disease peptides and the precision side of the platform
Section six: the wellness peptide market is borrowing legitimacy from real drug development
Section seven: what is conclusive, what is promising, and what is still noise
Section eight: the real breakthrough is engineered signaling biology, not “peptides”
Abstract
Peptides are running two simultaneous revolutions and almost nobody is talking about them as separate stories.
Real revolution: GLP-1 and GIP/GLP-1 agonism is now backed by hard outcomes data across cardiovascular events (SELECT, 20% MACE reduction), kidney disease (FLOW, 24% reduction in major kidney outcomes), heart failure with preserved ejection fraction plus obesity (SUMMIT, 38% reduction in worsening HF events), obstructive sleep apnea (SURMOUNT-OSA), and steatohepatitis (ESSENCE, 62.9% MASH resolution vs 34.3% placebo). Peptide radioligands like Lu-177 dotatate (NETTER-1, NETTER-2) and Lu-177 PSMA-617 (VISION, PSMAfore, PSMAddition) are turning small targeting peptides into precision oncology delivery vehicles. CNP analogues (vosoritide) and PTH prodrugs (palopegteriparatide) are correcting specific developmental and endocrine defects. Peptide cancer vaccines targeting clean antigens like mutant KRAS (ELI-002 / AMPLIFY-201) and the DNAJB1-PRKACA fusion in fibrolamellar carcinoma are producing credible immune and clinical signals in MRD settings.
Wellness grift running in parallel: BPC-157, TB-500, MOTS-c, Semax, Epitalon, DSIP, KPV, CJC-1295, ipamorelin, AOD-9604, and friends are sold by longevity clinics and “research use only” mail-order vendors with claims far ahead of any human RCT. FDA classifies most of these as Category 2 (substances with safety concerns) for 503A compounding. DOJ has prosecuted at least one major compounder. WADA has banned several. Zero of these have a published large-scale, randomized, placebo-controlled human trial behind them.
Major disappointments in the legit pipeline that the press has mostly underplayed: oral semaglutide failed both phase 3 Alzheimer’s trials (EVOKE and EVOKE+), exenatide failed phase 3 in Parkinson’s (Exenatide-PD3), CagriSema missed its 25% weight loss target and lost a head-to-head non-inferiority test against tirzepatide (REDEFINE 4), and efruxifermin missed its primary endpoint in compensated MASH cirrhosis at week 36.
Misreported as a problem when it isn’t: GLP-1 suicidality. FDA’s 2026 review found no increased risk and asked sponsors to remove the warning language.
Misreported as a solution when it isn’t yet: Stanford’s BRP peptide (“natural Ozempic”) is mouse and minipig data, no humans.
What this essay argues:
The real story is not “peptides.” It is engineered signaling biology, which is now mature enough to power generational therapeutic categories.
The wellness peptide market is borrowing the halo of these drugs and the regulatory enforcement gap is widening.
Investors, operators, and clinicians who treat “peptide” as a single category are going to make bad decisions in both directions, missing real platform opportunities and tolerating products that do not have the evidence to justify their claims.
Section one: peptides are not supplements, they are programmable physiology
There is a vocabulary problem at the heart of the peptide conversation and it is doing real damage. The word peptide covers semaglutide, which has multi-organ outcome data across hundreds of thousands of patient-years of exposure, and it also covers some sketchy vial labeled “BPC-157, research use only, not for human consumption” sold through a mail-order site that takes crypto. Same word. Wildly different things. A peptide is just a short chain of amino acids, usually defined as somewhere under fifty residues, longer than that and you are calling it a protein. So the category includes everything from insulin (which is technically two short chains) through GLP-1 agonists, somatostatin analogues, calcitonin gene-related peptide blockers, gonadorelin analogues, and the entire pipeline of next-gen incretin agonists and peptide vaccines. The point is, “peptide” tells you almost nothing about the molecule’s pharmacology, evidence base, regulatory status, or risk profile. It just tells you the chemistry class.
The right way to think about peptides is as programmable signaling. Most peptide drugs are doing one of a few things: agonizing or antagonizing a receptor that evolved to bind an endogenous peptide hormone (GLP-1, GIP, glucagon, amylin, somatostatin, PTH, ANP, CNP, the melanocortins), serving as a homing ligand to deliver a payload (Lu-177 dotatate, Lu-177 PSMA-617, melflufen), presenting a tumor antigen to the immune system (neoantigen vaccines, mutant KRAS vaccines, fusion antigen vaccines), or modulating immunity directly (some antimicrobial peptides, some immune checkpoint adjacent work). What unites the legitimate side of the field is that the drug exploits a specific, characterized pathway with a specific, measurable target engagement story. Receptor binding kinetics, downstream signaling, pharmacokinetics, dose response, the whole boring drug development apparatus. What unites the wellness side of the field is that none of that is true. The mechanism is hand-waved at, the dosing is whatever the clinic feels like, the manufacturing chain is opaque, and the evidence base is rodent studies plus testimonials.
The reason this matters now and not five years ago is that the credible side of peptide medicine has reached escape velocity. GLP-1 agonism has the cleanest cardiometabolic outcomes data of any drug class developed in the last twenty years, peptide radioligands are eating into solid tumor categories that were considered locked, peptide cancer vaccines are showing real immune readouts in pancreatic cancer and rare hepatocellular variants, and the manufacturing economics for peptides have improved enough that the field is starting to compete with small molecules on cost. Meanwhile, the wellness peptide market is also at escape velocity, just on TikTok instead of in NEJM. Both things are happening at once, both are using the same word, and most healthcare media coverage flattens them into a single story.
Section two: GLP-1s proved peptide drugs can change hard outcomes, not just biomarkers
